Upgrade to see committee overlap, performance context, and full expert analysis.
KDP congressional trades
7 matched disclosures
KDP congressional trades snapshot
This page summarizes public STOCK Act disclosures involving KDP. It is useful for seeing which lawmakers reported KDP transactions, how many filings are visible, the buy/sell mix, and whether the newest public filing describes a recent or delayed trade.
Oct 22, 2025
Public House and Senate STOCK Act disclosures normalized by Congressional Trader.
Filing date can trail transaction date. This page is for research and monitoring, not investment advice.
What the KDP congressional trade page shows
Congressional Trader tracks 7 public STOCK Act disclosures for KDPacross 4 lawmakers. This page separates purchases from sales, shows filing delays, and links each disclosure back to the individual politician profile when available.
The most recent KDP filing shown here was filed on Oct 22, 2025 by Lisa C. McClain as a sale. Related lawmakers include Lisa C. McClain, Robert P. Bresnahan, Val T. Hoyle, Julie Johnson.
Top lawmakers for KDP
Pro performance summary
Unlock 30/90-day post-trade summaries, committee overlap, and CSV-oriented research views for high-intent ticker research.
Compare Pro plansUpgrade to see committee overlap, performance context, and full expert analysis.
Upgrade to see committee overlap, performance context, and full expert analysis.
Upgrade to see committee overlap, performance context, and full expert analysis.
Upgrade to see committee overlap, performance context, and full expert analysis.
Upgrade to see committee overlap, performance context, and full expert analysis.
Upgrade to see committee overlap, performance context, and full expert analysis.
FAQ
Which lawmakers traded KDP?
Recent KDP disclosures include Lisa C. McClain, Robert P. Bresnahan, Val T. Hoyle, Julie Johnson.
What is the buy/sell mix for KDP?
The visible sample currently shows 3 purchases and 4 sales or partial sales.
Should I trade based on KDP disclosures?
No. This page summarizes public filings for research and monitoring. It is not investment advice.